Medivir’s history

MIV-818 was selected as a candidate drug (CD) from the company’s project for the treatment of hepatocellular carcinoma.
The subsidiary BioPhausia (Nordic Brands) was divested to Karo Pharma AB.
The exclusive rights to the hepatitis C project, MIV-802, was outlicensed to Trek Therapeutics.
The first oncology project within hepatocellular cancer was generated from the new focus area oncology.
SEK 600 million was transferred to the shareholders through a voluntary redemption programme.
MIV-802 was selected as a candidate drug for the treatment of hepatitis C infection.
Simeprevir approved in the EU and Russia for the treatment of adults with chronic hepatitis C.
Olysio and Adasuve launched in Sweden, Norway, Finland and Denmark.
Simeprevir was was approved for the treatment of patients with chronic hepatitis C in Japan, Canada and USA.
MIV-247 was selected as a candidate drug and enters development for the treatment of neuropathic pain.
Registration application for Simeprevir submitted in Japan, USA and Europe.
Positive phase III data reported for simeprevir, confirming that treatment with simeprevir in combination with interferon and ribavirin results in high cure rates, a good safety profile, and reduced treatment times.
Global phase III trials of simeprevir begin.
The North American marketing rights to Xerclear are sold to Meda.
BioPhausia acquired in order to strengthen the commercial platform.
Meda licenses the sales and marketing rights for Xerclear for North America, Mexico and Canada. Corresponding rights licensed by GlaxoSmithKline for OTC sales in Europe.
Xerclear approved for sale in certain European markets and the US market.
Phase III trials of Xerclear begin.
Hepatitis C agreement signed with Tibotec/Janssen for simeprevir.
Mimetrix UK acquired in order to strengthen and expand within the protease sphere.
Medivir listed on the Stockholm Stock Exchange. Collaboration with Abbott begins.
CCS, Clean Chemical Sweden AB, a Sweden-based manufacturer of skincare products, acquired.
Collaboration agreements entered into with Eli Lilly for HIV, and with Wellcome.
Collaboration agreement entered into with American Cyanamid for HIV.
Medivir founded.

Page updated 15 May 2017